Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: Novel structures and developments during 2006-2008

Current Topics in Medicinal Chemistry

Volumn 8, Issue 16, 2008, Pages 1452-1467

  Pettus, Liping H ^a   Wurz, Ryan P ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 QUINAZOLINYL 4 METHYLBENZAMIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 7 AMINONAPHTHYRIDONE; ALPHA METHYLBENZYLAMIDE; AMIDE; ANTIINFLAMMATORY AGENT; ARRY 797; BENZAMIDE DERIVATIVE; BIPHENYLAMIDE; BMS 640994; CYANOPYRIMIDINE; CYCLOPROPYLBENZAMIDE; CYCLOPROPYLMETHYLAMIDE; DORAMAPIMOD; ISOQUINOLINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NICOTINAMIDE; PHTHALAZINYLBENZAMIDE DERIVATIVE; PICOLINAMIDE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRROLOTRIAZINE; QUINAZOLINYLBENZAMIDE; R 1487; RO 3201195; SCIO 469; TRIAZOLOPYRIDENE; UNCLASSIFIED DRUG; VX 702; ETHER DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; INFLAMMATORY DISEASE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHARMACODYNAMICS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; INFLAMMATION; METABOLISM;

ANIMALS; BENZAMIDES; ETHERS; HUMANS; INFLAMMATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58149190433     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608786264245     Document Type: Review

References (102)

1. (a) O'Keefe, S. J.; Mudgett, J. S.; Cupo, S.; Parsons, J. N.; Chartrain, N. A.; Fitzgerald, C.; Chen, S.-L.; Lowitz, K.; Rasa, C.; Visco, D.; Luell, S.; Carballo-Jane, E.; Owens, K.; Zaller, D. M. Chemical Genetics Define the Roles of p38α and p38β in Acute and Chronic Inflammation. J. Biol. Chem. 2007, 282, 34663-34671.
2. (b) Lee, J. C.; Newton, R.; Holden, N. Inhibitors of p38 Mitogen-Activated Protein Kinase Potential as Anti-Inflammatory Agents in Asthma. Bio. Drugs 2003, 17, 113-129.
3. (c) Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem. 2001, 38, 1-60.
4. (a) Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497.
5. (b) Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
6. (c) Tracey, K. J.; Cerami, A. Annu. Rev. Cell Biol. 1993, 9, 317-343.
7. (a) Goldsmith, D. R.; Wagstaff, A. J. Spotlight on Etanercept in plaque psoriasis and psoriatic arthritis. Bio. Drugs 2005, 19, 401-403.
8. (b) Feldman, S. R.; Gordon, K. B.; Bala, M.; Evans, R.; Li, S.; Dooley, L. T.; Guzzo, C.; Patel, K.; Menter, A.; Gottlieb, A. B. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br. J. Derm. 2005, 152, 954-960.
9. (c) Moreland, L. W. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum. Dis. Clin. North Am. 1998, 24, 579-591.
10. (d) Bang, L. M.; Keating, G. M. Adalimumab: A review of its use in rheumatoid arthritis. Bio Drugs 2004, 18, 121-139.
11. (a) Gaestal, M.; Mengel, A.; Bothe, U.; Asadullah K. Protein Kinases as Small Molecule Inhibitor Targets in Inflammation. Curr. Med. Chem. 2007, 14, 2214-2234.
12. (b) Peifer, C.; Wagner, G.; Laufer, S. New Approaches to the Treatment of Inflammatory Disorders Small Molecule Inhibitors of p38 MAP Kinase. Curr. Top. Med. Chem. 2006, 6, 113-149.
13. (c) Norman, P. Allosteric p38 kinase inhibitors. Expert Opin. Ther. Patents 2006, 16, 1443-1448.
14. (d) Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
15. A selection of the 2005 reviews on p38 MAP kinase include: (a) Dominguez, C.; Powers, D. A.; Tamayo, N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr. Opin. Drug Disc. Dev. 2005, 8, 421-430.
16. (b) Dominguez, C.; Tamayo, N.; Zhang, D. p38 Inhibitors: beyond pyridinylimidazoles. Expert Opin. Ther. Patents 2005, 15, 801-816.
17. (c) Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38α protein. Curr. Med. Chem. 2005, 12, 2979-2994.
18. (d) Goldstein, D. M.; Gabriel, T. Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. 2005, 5, 1017-1029.
19. (e) Natarajan, S. R.; Doherty, J. B. p38 MAP Kinase Inhibitors: Evolution of Imidazole-Based and Pyrido-Pyrimidin-2-One Lead Classes. Curr. Top. Med. Chem. 2005, 5, 987-1003.
20. (f) Hynes, J.; Leftheris, K. Small molecule p38 inhibitors: Novel structural features and advances from 2002-2005. Curr. Top. Med. Chem. 2005, 5, 967-985.
21. (g) Diller, D. J.; Lin, T. H.; Metzger, A. The Discovery of Novel Chemotypes of p38 Kinase Inhibitors. Curr. Top. Med. Chem. 2005, 5, 953-965.
22. Margutti, S.; Laufer, S. A. Are MAP Kinases Drug Targets? Yes, but Difficult Ones. ChemMedChem 2007, 2, 1116-1140.
23. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Keys, J. R.; Land Vatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
24. DiMauro, E. F.; Newcomb, J.; Nunes, J. J.; Bemis, J. E.; Boucher, C.; Buchanan, J. L.; Buckner, W. H.; Cee, V.; Chai, L.; Deak, H. L.; Epstein, L. F.; Faust, T.; Gallant, P.; Geuns-Meyer, S. D.; Gore, A.; Gu, Y.; Henkle B.; Hodous, B. L.; Hsieh, F.; Huang, X.; Kim, J. L.; Lee, J. H.; Martin, M. W.; Masse, C. E.; McGowan, D. C.; Metz, D.; Mohn, D.; Morgenstern, K. A.; Oliveira-dos-Santos, A.; Patel, V. F.; Powers, P.; Rose, P. E.; Schneider, S.; Tomlinson, S. A.; Tudor, Y.-Y.; Turci, S. M.; Welcher, A. A.; White, R. D.; Zhao, H.; Zhu, L.; Zhu, X. Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR and in Vivo Anti-Inflammatory Activity. J. Med. Chem. 2006, 49, 5671-5686.
25. Patel, V. F.; Kim, J. L.; Geuns-Meyer, S. D.; Chaffee, S. C.; Cee, V. J.; Hodous, B. L.; Bellon, S.; Harmange, J.-C.; Olivieri, P. R.; Thaman, M. C.; Dimauro, E. F.; Buchanan, J. L.; Mcgowan, D. C.; Albrecht, B. K.; Deak, H. L.; Bemis, J. E.; White, R.; Martin, M. W.; Habgood, G. J.; Tempest, P. A.; Masse, C. E.; Buckner, W. H.; Herberich, B. J.; Graceffa, R.; Zhang, D.; Xu, S.; Sham, K.; Rzasa, R. M.; Falsey, J.; Chakrabarti, P. P.; Cao, G.-Q.; Tomlinson, S. A.; Pettus, L. H.; Smith, A. L.; Paras, N. A.; Liu, G.; Demorin, F. F.; Tasker, A.; Reed, A. Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases. WO 2006039718, Apr. 13, 2006.
26. (a) Tasker, A.; Zhang, D.; Cao, G.-Q.; Chakrabarti, P.; Falsey, J.; Herberich, B. J.; Hungate, R. W.; Pettus, L. H.; Reed, A.; Rzasa, R. M.; Sham, K.; Thaman, M. C.; Xu, S. Preparation of phthalazine, aza- and diaza-phthalazine compounds as protein kinase, especially p38 kinase, inhibitors for treating inflammation and related conditions. WO 2006094187, Sep. 8, 2006.
27. (b) Tasker, A.; Zhang, D.; Pettus, L. H.; Rzasa, R. M.; Sham, K.; Xu, S.; Chakrabarti, P. Phthalazine, aza- and diaza-phthalazine compounds and methods of use. WO 2008030466, Mar. 13, 2008.
28. Herberich, B.; Cao, G.-Q.; Chakrabarti, P.; Falsey, J.; Pettus, L.; Rzasa, R. M.; Reed, A. B.; Reichelt, A.; Sham, K.; Thaman, M.; Wurz, R. P.; Xu, S.; Zhang, D.; Hsieh, F.; Tudor, Y.; Yu, V.; Lee, M.; Rashid, S.; Mohr, C.; Plant, M.; Henkle, B.; Middleton, S.; Sherman, L.; Wong, L. M.; Tasker, A. S. Discovery of Highly Selective and Potent p38 Inhibitors Based on a Phthalazine Scaffold. J. Med. Chem. 2008, manuscript in press.
29. (a) PDB deposition number is 3DS6. (b) For other examples of flipped Gly110, see: Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10, 764-769.
30. Pettus, L. H.; Xu, S.; Cao, G.-Q.; Chakrabarti, P.; Rzasa, R.; Sham, K.; Wurz, R. P.; Zhang, D.; Middleton, S.; Henkle, B.; Plant, M.; Saris, C. J. M.; Sherman, L.; Wong, L. M.; Powers, D. A.; Tudor, Y.; Yu, V.; Lee, M. R.; Syed, R.; Hsieh, F.; Tasker, A. S. 3-Amino- 7-phthalazinyl-benzoisoxazoles as a Novel Class of Potent, Selective, and Orally Available Inhibitors of p38α MAP Kinase. J. Med. Chem. 2008. manuscript in press.
31. Human Kinome image is created and provided by Cell Signaling Technology, Inc. www.cellsignal.com.
32. Hong, F.-T.; Falsey, J. R.; Rzasa, R. M.; Tadesse, S.; Tasker, A. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use as p38 kinase inhibitors for treating inflammation disorders and other disease. WO 2007124181, Nov. 11, 2007.
33. Zhang, D.; Tasker, A.; Sham, K. C.; Chakrabarti, P. P.; Falsey, R. J.; Herberich, B. J.; Pettus, L. H.; Rzasa, R. M. Imidazo- and triazolo-pyridine compounds and methods of use thereof. WO 2008045393, Apr. 17, 2008.
34. (a) Angell, R. M.; Aston, N. M.; Bamborough, P.; Bamford, M. J.; Cockerill, G. S.; Merrick, S. J.; Walker, A. L. Preparation of 5′- carbamoyl-1,1′-biphenyl-4-carboxamides as p38 kinase inhibitors. WO 2003032980, Apr. 24, 2003.
35. (b) Angell, R. M.; Aston, N. M.; Bamborough, P.; Bamford, M. J.; Cockerill, G. S.; Flack, S. S.; Laine, D. I.; Merrick, S. J.; Smith, K. J.; Walker, A. L. Preparation of 5′-acylamino-1,1′-biphenyl-4-carboxamides as p38 kinase inhibitors. WO 2003032971, Apr. 24, 2003.
36. (c) Aston, N. M.; Bamborough, P.; Walker, A. L. Preparation of nicotinamides as p38 inhibitors. WO 2003068747, Aug. 21, 2003.
37. Chandi, A.; Keel, T. R.; Patel, V. K.; Walker, A. L. N-(2,2- dimethylpropyl)-6-(3-fluoro-5-((3-isoxazolylamino)carbonyl)-2- methylphenyl)-3-pyridinecarboxamide. WO 2006134382, Dec. 21, 2006.
38. Angell, R. M.; Bamborough, P.; Cleasby, A.; Cockerill, S. G.; Jones, K. L.; Mooney, C. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode. Bioorg. Med. Chem. Lett. 2008, 18, 318-323.
39. Angell, R. M.; Angell, T. D.; Bamborough, P.; Brown, D.; Brown, M.; Buckton, J. B.; Cockerill, S. G.; Edwards, C. D.; Jones, K. L.; Longstaff, T.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L.; Willson, M. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR. Bioorg. Med. Chem. Lett. 2008, 18, 324-328.
40. Barker, M. D.; Hamblin, J. N.; Jones, K. L.; Patel, V. K.; Swanson, S.; Walker, A. L. p38 Kinase inhibitors. US 20070161673, Jul. 12, 2007.
41. (a) Angell, R. M.; Baldwin, I. R.; Bamborough, P.; Deboeck, N. M.; Longstaff, T.; Swanson, S. Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I. A. rheumatoid arthritis. US 20060122221, Jun. 8, 2006.
42. (b) Campos, S. A.; Swanson, S.; Walker, A. L. Fused hetereoaryl derivatives for use as p38 inhibitors in the treatment of I. A. rheumatoid arthritis. US 20070142372, Jul. 21, 2007.
43. Wrobleski, S. T.; Doweyko, A. M. Structural comparison of p38 inhibitor-protein complexes: A review of recent p38 inhibitors having unique binding interactions. Curr. Top. Med. Chem. 2005, 5, 1005-1016.
44. Das, J.; Moquin, R. V.; Pitt, S.; Zhang, R.; Shen, D. R.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Sack, J. S.; Zhang, H.; Kiefer, S. E.; Kish, K.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. Pyrazolo-Pyrimidines: A Novel Heterocyclic Scaffold for Potent and Selective p38α Inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2652-2657.
45. Hynes, J. Jr.; Dyckman, A. J.; Lin, S.; Wrobleski, S. T.; Wu, H.; Gillooly, K. M.; Kanner, S. B.; Lonial, H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Yang, X.; Zhang, R.; Behnia, K.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Tokarski, J. S.; Sack, J. S.; Pokross, M.; Kiefer, S. E.; Newitt, J. A.; Barrish, J. C.; Dodd, J.; Schieven, G. L.; Leftheris, K. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)- pyrrolo[2,1-f][1,2,4]triazine p38α mitogen-activated protein kinase inhibitors. J. Med. Chem. 2008, 51, 4-16.
46. Wrobleski, S. T.; Lin, S.; Hynes, J. Jr.; Wu, H.; Pitt, S.; Shen, D. R.; Zhang, R.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W.; Doweyko, A. M.; Kish, K. F.; Tredup, J. A.; Duke, G. J.; Sack, J. S.; McKinnon, M.; Dodd, J.; Barrish, J. C.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of New Pyrrolo[2,1-f][1,2,4]triazines as Potent p38α MAP Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2739-2744.
47. Lin, J.; Wrobleski, S. T.; Liu, C.; Leftheris, K. Tricyclic-heteroaryl compounds useful as kinase inhibitors. US 7253167, Aug. 7, 2008.
48. Hynes, J. Jr.; Wu, H.; Pitt, S.; Shen, D. R.; Zhang, R.; Schieven, G. L.; Gillooly, K. M.; Shuster, D. J.; Taylor, T. L.; Yang, X.; McIntyre, K. W.; McKinnon, M.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Kish, K.; Kiefer, S. E.; Sack, J. S.; Newitt, J. A.; Barrish, J. C.; Dodd, J.; Leftheris, K. The discovery of (R)-2-(sec-butylamino)- N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994) - A potent and efficacious p38α MAP kinase inhibitor. Bioorg. Med. Chem. Lett. 2008, 18, 1762-1767.
49. (a) Dyckman, A. J.; Das, J.; Leftheris, K.; Liu, C.; Moquin, R. V.; Wrobleski, S. T. Pyrazole-amine compounds useful as kinase inhibitors. US 20080004278, Jan. 3, 2008.
50. (b) Dyckman, A.; Das, J.; Leftheris, K.; Liu, C.; Zhao, R.; Chen, B.-C.; Wrobleski, S. T. Preparation of aryl-substituted pyrazole-amide compounds useful as kinase inhibitors. WO 2004099156, Nov. 11, 2004.
51. (a) Lang, H.; Lan, J.; Fang, Y. p-38 kinase inhibitors. US 20070111999, May 17, 2007.
52. (b) Dong, Q.; Wang, J.; Lang, H.; Lan, J. Bicyclic heterocyclic p-38 kinase inhibitors. US 20070142405, Jun. 21, 2007.
53. Ferraccioli, G. F. VX-745 Vertex Pharmaceuticals. Curr. Opin. Anti-Inflammat. Immunomodul. Investig. Drugs 2000, 2, 74-77.
54. Mohanlal, R.; Kauffman, R.; Alam, J.; Godfrey, C.; Kadiyala, I. Compositions and methods for treating rheumatoid arthritis. WO 2007103468, Sep. 13, 2007.
55. (a) http://www.vpharm.com/ current-projects/drug-candidates/VX-702. html
56. (b) Ding, C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Investig. Drugs 2006, 7, 1020-1025.
57. (a) Salituro, F.; Galullo, V.; Bellon, S.; Bemis, G.; Cochran, J. Inhibitors of p38. US 20070142334, Jun. 21, 2007.
58. (b) Bemis, G. W.; Salituro, F. G.; Duffy, J. P.; Cochran, J. E.; Harrington, E. M.; Murcko, M. A.; Wilson, K. P.; Su, M.; Galullo, V. P. Inhibitors of p38. US 7365072, Apr. 29, 2008.
59. Natarajan, S. R.; Liu, L.; Levorse, M.; Thompson, J. E.; O'Neill, E. A.; O'Keefe, S. J.; Vora, K. A.; Cvetovich, R.; Chung, J. Y.; Carballo-Jane, E.; Visco, D. M. p38 MAP kinase inhibitors. Part 5: Discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Bioorg. Med. Chem. Lett. 2006, 16, 5468-5471.
60. Doherty, J. B.; Natarajan, S. R.; Stelmach, J. E. (Halo-benzo carbonyl) heterobicyclic p38 kinase inhibiting agents. US 7314873, Jan. 1, 2008.
61. Chen, M.-H.; Doherty, J. B.; Tynebor, R. p38 kinase inhibiting agents. WO 2007067478, Jun. 14, 2007.
62. Natarajan, S. R.; Heller, S. T.; Nam, K.; Singh, S. B.; Scapin, G.; Patel, S.; Thompson, J. E.; Fitzgerald, C. E.; O'Keefe, S. J. p38 MAP kinase inhibitors. Part 6: 2-Arylpyridazin-3-ones as templates for inhibitor design. Bioorg. Med. Chem. Lett. 2006, 16, 5809-5813.
63. Caturla Javaloyes, J. F.; Vidal Gispert, L.; Lumeras Amador, W. 1,7-Naphthyridine derivatives as p38 MAP kinase inhibitors. WO 2008017461, Feb. 14, 2008.
64. Vidal Juan, B.; Caturla Javaloyes, J. F.; Lumeras Amador, W.; Vidal Gispert, L. New pyridin-3-amine derivatives. WO 2007096072, Aug. 30, 2007.
65. Boehm, T. L.; Christie, L. C.; Devadas, B.; Madsen, H. M.; Marrufo, L; Selness, S. Substituted N-Alkylpyrimidinones. WO 2006040666, Apr. 20, 2006.
66. Selbo, J. G. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidine-1(6H)-yl]-N-(2-hydroxyethyl)-4- methylbenzamide. WO 2006040649, Apr. 20, 2006.
67. Moffat, D. C. F.; Pintat, S.; Davies, S. p38 MAP kinase inhibitors. WO 2007129040, Nov. 15, 2007.
68. Gabriel, T. Pathway to the Clinic: Inhibition of p38 MAP Kinase. Cambridge Healthtech Institute's International Molecular Medicine Tri-Conference San Francisco, California, Feb. 28-Mar. 2, 2007.
69. Goldstein, D. M.; Alfredson, T.; Bertrand, J.; Browner, M. F.; Clifford, K.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; La Fargue, J.; Lapierre, J. M.; Larrabee, S.; Li, F.; Papp, E.; McWeeney, D.; Ramesha, C.; Roberts, R.; Rotstein, D.; San Pablo, B.; Sjogren, E. B.; So, O.-Y.; Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, M.; Welch, T.; Weller, P.; Whiteley, P. E.; Young, K.; Zipfel, S. Discovery of S-[5-Amino-1-(4-fluorophenyl) -1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy) phenyl]methanone (RO3201195), an Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase. J. Med. Chem. 2006, 49, 1562-1575.
70. Goldstein, D. M. Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones. US 7348331, Mar. 25, 2008.
71. Goldstein, D. M.; Hawley, R. C.; Lui, A. S.-T.; Sjogren, E. B. Imidazo-substituted compounds as p38 kinase inhibitors. US 7285559, Oct. 23, 2007.
72. (a) Billedeau, R. J.; Dewdney, N. J.; Gabriel, T. p38 MAP kinase inhibitors and methods for using the same. WO 2007023111, Mar.1, 2007.
73. (b) Arora, N.; Arzeno, H. B.; Billedeau, R. J.; Dewdney, N. J.; Durkin, K.; Gabriel, T.; McCaleb, K. L.; Soth, M. p38 MAP kinase inhibitors and methods for using the same. WO 2007023110, Mar. 1, 2007.
74. Revesz, L.; Blum, E.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Neumann, U.; Rucklin, G. Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity. Bioorg. Med Chem. Lett. 2006, 16, 262-266.
75. Array BioPharma website: http://63.251.142.244/ProductPipeline/ Inflamation.asp
76. (a) Munson, M.; Hunt, K. W.; Clark, C.; Kim, G.; Burgess, L.; Rizzi, J. p38 inhibitors and methods of use thereof. WO 2007126871, Nov. 8, 2007.
77. (b) Munson, M.; Rizzi, J.; Kim, G. p38 inhibitors and methods of use thereof. WO 2006122230, Nov. 16, 2006.
78. Burgess, L. E. Design, Discovery and Lead Optimization of p38 MAPK Inhibitors. 14th Internat. Inflammat. Res. Associat. Conf. Oct. 18, 2006.
79. Moss, N.; Breitfelder, S.; Betageri, R.; Cirillo, P. F.; Fadra, T.; Hickey, E. R.; Kirrane, T.; Kroe, R. R.; Madwed, J.; Nelson, R. M.; Pargellis, C. A.; Qian, K. C.; Regan, J.; Swinamer, A.; Torcellini, C. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorg. Med. Chem. Lett. 2007, 17, 4242-4247.
80. Goldberg, D. R.; Hao, M.-H.; Qian, K. C.; Swinamer, A. D.; Gao, D. A.; Xiong, Z.; Sarko, C.; Berry, A.; Lord, J.; Magolda, R. L.; Fadra, T.; Kroe, R. R.; Kukulka, A.; Madwed, J. B.; Martin, L.; Pargellis, C.; Skow, D.; Song, J. J.; Tan, Z.; Torcellini, C. A.; Zimmitti, C. S.; Yee, N. K.; Moss, N. Discovery and Optimization of p38 Inhibitors via Computer-Assisted Drug Design. J. Med. Chem. 2007, 50, 4016-4026.
81. Cogan, D. A.; Aungst, R.; Breinlinger, E. C.; Fadra, T.; Goldberg, D. R.; Hao, M. H.; Kroe, R.; Moss, N.; Pargellis, C. P.; Qian, K. C.; Swinamer, A. D. Structure-based Design and Subsequent Optimization of 2-Tolyl-(1,2,3-triazol-1-yl-4-carboxamide) Inhibitors of p38 MAP Kinase. Bioorg. Med. Chem. Lett. 2008, 3251-3255.
82. Montalban, A. G.; Boman, E.; Chang, C.-D.; Ceide, S. C.; Dahl, R.; Dalesandro, D.; Delaet, N. G. J.; Erb, E.; Ernst, J. T.; Gibbs, A.; Kahl, J.; Kessler, L.; Lundström, J.; Miller, S.; Nakanishi, H.; Roberts, E.; Saiah, E.; Sullivan, R.; Wang, Z.; Larson, C. J. The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 1772-1777.
83. Barnes, M. J.; Conroy, R.; Miller, D. J.; Mills, J. S.; Montana, J. G.; Pooni, P. K.; Showell, G. A.; Walsh, L. M.; Warneck, J. B. H. Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: A new use of silicon bioisosteres in medicinal chemistry. Bioorg. Med. Chem. Lett. 2007, 17, 354-357.
84. (a) Flynn, D. L.; Petillo, P. A. Anti-inflammatory medicaments. US 7342037, Mar. 11, 2008.
85. (b) Flynn, D. L.; Petillo, P. A. Anti-inflammatory medicaments. WO 2006014290, Feb. 9, 2006.
86. De Dios, A.; Garcia-Paredes, C.; Lopez de Uralde Garmendia, B.; Mader, M. M.; Pobanz, M. A.; Shih, C.; Zhong, B. Pyrazoleisoquinoline urea derivatives as p38 kinase inhibitors. WO 2007053346, May 10, 2007.
87. Gill, A. L.; Woodhead, S.; Carr, M. 5-Amino-2-carbonylthiophene derivatives for use a p38 MAP kinase inhibitors in the treatment of inflammatory diseases. US 20070082898, Apr. 12, 2007.
88. Ashwell, M. A.; Liu, Y.; Ali, S.; Hill, J.; Wrona, W. 1,4-Disubstituted naphthalenes as inhibitors of p38 MAP kinase. US 20080032967, Feb. 7, 2008.
89. (a) Mathias, J. P.; Milan, D. S.; Lewthwaite, R. A.; Phillips, C. Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors. WO 2006018718, Feb. 23, 2006.
90. (b) Lewthwaite, R. A.; Mathias, J. P.; Phillips, C. Triazolopyridine compounds. WO 2007091152, Aug. 16, 2007.
91. Devadas, B.; Hartmann, S. J.; Heier, R. F. III.; Jerome, K. D.; Kolodziej, S. A.; Mathias, J. P.; Norton, M. B.; Promo, M. A.; Rucker, P. V.; Selness, S. R. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives. WO 2007091176, Aug. 16, 2007.
92. (a) Lee, K.; Tong, S.; Beckerman, T. Pharmaceutical formulations of an indole-type derivative and related method of use. WO 2008024391, Feb. 28, 2008.
93. (b) Chiarella, R. A. Co-crystals of (2R-trans)-6-chloro-5- 4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N, N,1-trimethyl-alpha-oxo-1H-indole-3-acetamide. WO 2008013823, Jan. 31, 2008.
94. Dugar, S. 7th World Congress on Inflammation, Melbourne, Australia, Aug. 20-24, 2005.
95. Nikas, S. N.; Drosos, A. A. SCIO-469 (Scios Inc). Curr. Opin. Investig. Drugs 2004, 5, 1205-1212.
96. Dhar, T. G. M.; Wrobleski, S. T.; Lin, S.; Furch, J. A.; Nirschl, D. S.; Fan, Y.; Todderud, G.; Pitt, S.; Doweyko, A. M.; Sack, J. S.; Mathur, A.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of p38 MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg. Med. Chem. Lett. 2007, 17, 5019-5024.
97. Protter, A. A.; Svensson, C.; Yaksh, T.; Cordell, B.; Dugar, S. Treatment of pain by inhibition of p38 MAP kinase. US 20080039461, Feb. 14, 2008.
98. Dugar, S.; Goyal, B.; Lu, Q.; Leudtke, G. R.; Mavunkel, B. J.; Nashashibi, I.; Perumattam, J. J.; Tan, X.; Tester, R. Azaindole derivatives as inhibitors of p38 kinase. WO 2006112828, Oct. 16, 2008.
99. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Dugar, S.; Lu, Q.; Liang, X. Benzofuran derivatives as inhibitors of p38-α kinase. US 7189726, Mar. 13, 2007.
100. Mavunkel, B.; Dugar, S.; Luedtke, G.; McEnroe, G.; Tan, X. Piperidine/ piperazine-type inhibitors of p38 kinase. US 20070185112, Aug. 9, 2007.
101. Mavunkel, B. J.; Dugar, S.; Luedtke, G. R.; Tan, X.; McEnroe, G. Piperidine/piperazine-type inhibitors of p38 kinase. US 7214679, May 8, 2007.
102. Information on the ongoing clinical trials can be found at: http://clinicaltrials.gov